GuptaAK, JainHC, LyndeCW, et al: Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol43: 244, 2000.
GuptaAK, JainHC, LyndeCW, et al: Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol43: 244, 2000.10.1067/mjd.2000.10479410906646)| false
KumarS, KimballAB: New antifungal therapies for the treatment of onychomycosis. Expert Opin Investig Drugs18: 727, 2009.1942611810.1517/13543780902810352http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000267274800003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3)| true
OgasawaraYM, HirumaM, MutoH, et al: Clinical and mycological study of occult tinea pedis and tinea unguium in dermatological patients from Tokyo. Mycoses46: 114, 2003.1287019910.1046/j.1439-0507.2003.00855.x)| false
PereaS, RamosMJ, GarauM, et al: Prevalence and risk factors of tinea unguium and tinea pedis in the general population in Spain. J Clin Microbiol38: 3226, 2000.1097036210.1128/JCM.38.9.3226-3230.2000)| false
SzepietowskiJC, ReichA, GarlowskaE, et al: Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol142: 1279, 2006.1704318210.1001/archderm.142.10.1279)| false
UngpakornR, LohaprathanS, ReangchainamS: Prevalence of foot diseases in outpatients attending the Institute of Dermatology, Bangkok, Thailand. Clin Exp Dermatol29: 87, 2004.10.1111/j.1365-2230.2004.01446.x14723731)| false
ElewskiBE, RichP, PollakR, et al: Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase 3 multicenter, randomized, double-blind studies. J Am Acad Dermatol68: 600, 2013.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000317201100019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.jaad.2012.10.013)| true
We sought to evaluate the efficacy of efinaconazole topical solution, 10%, in patients with onychomycosis and coexisting tinea pedis.
We analyzed 1,655 patients, aged 18 to 70 years, randomized (3:1) to receive efinaconazole topical solution, 10%, or vehicle from two identical multicenter, double-blind, vehicle-controlled 48-week studies evaluating safety and efficacy. The primary end point was complete cure rate (0% clinical involvement of the target toenail and negative potassium hydroxide examination and fungal culture findings) at week 52. Three groups were compared: patients with onychomycosis and coexisting interdigital tinea pedis on-study (treated or left untreated) and those with no coexisting tinea pedis.
Treatment with efinaconazole topical solution, 10%, was significantly more effective than vehicle use irrespective of the coexistence of tinea pedis or its treatment. Overall, 352 patients with onychomycosis (21.3%) had coexisting interdigital tinea pedis, with 215 of these patients (61.1%) receiving investigator-approved topical antifungal agents for their tinea pedis in addition to their randomized onychomycosis treatment. At week 52, efinaconazole complete cure rates of 29.4% were reported in patients with onychomycosis when coexisting tinea pedis was treated compared with 16.1% when coexisting tinea pedis was not treated. Both cure rates were significant compared with vehicle (P = .003 and .045, respectively), and in the latter subgroup, no patients treated with vehicle achieved a complete cure.
Treatment of coexisting tinea pedis in patients with onychomycosis enhances the efficacy of once-daily topical treatment with efinaconazole topical solution, 10%.